Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Hitachi builds cell plant in Japan

by Jean-François Tremblay
October 31, 2016 | A version of this story appeared in Volume 94, Issue 43

Hitachi Chemical will spend $19 million to build a custom manufacturing facility producing live regenerative-medicine cells in Yokohama, Japan. The cells, produced in vitro at the facility, could be used for organ restoration or to repair immune functions damaged by injury or disease. Other applications are in cancer immunotherapy treatments and somatic stem cell therapy. The plant will make use of know-how and technology supplied by PCT, a subsidiary of Caladrius BioSciences in which Hitachi acquired a 20% stake for close to $20 million in March.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.